A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA) Meeting Abstract
| Authors: | Powles, T.; Meeks, J. J.; Galsky, M. D.; Van der Heijden, M. S.; Nishiyama, H.; Al-Ahmadie, H. A.; Goluboff, E. T.; Hois, S.; Donegan, S. E.; Williams, V.; Xiao, F.; Catto, J. W. F. |
| Abstract Title: | A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA) |
| Meeting Title: | 2021 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2021 Feb 11-13 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-02-20 |
| Language: | English |
| ACCESSION: | WOS:000636801500047 |
| DOI: | 10.1200/JCO.2021.39.6_suppl.TPS505 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS505 -- Source: Wos |
